Sucampo Pharma (SCMP) Misses Q3 EPS by 1c; Boosts FY14 Earnings Outlook

Sucampo Pharma (NASDAQ: SCMP) reported Q3 EPS of $0.03, $0.01 worse than the analyst estimate of $0.04. Revenue for the quarter came in at $31.5 million versus the consensus estimate of $26.11 million.

Sucampo raised its full year 2014 earnings guidance to $15.0 million to $20.0 million net income, excluding special items, versus previous guidance of $4.0 million to $6.0 million.

For earnings history and earnings-related data on Sucampo Pharma (SCMP) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Diana Shipping withdraws bid to acquire Genco Shipping
• SVB & T Corporation (SVBT) Tops Q2 EPS by 275c